Pharming Total Current Liabilities from 2010 to 2024
| PHAR Stock | USD 7.74 0.27 3.61% |
Total Current Liabilities | First Reported 2009-12-31 | Previous Quarter 79.9 M | Current Value 79.8 M | Quarterly Volatility 35.1 M |
Check Pharming Group financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pharming Group's main balance sheet or income statement drivers, such as Depreciation And Amortization of 16.7 M, Interest Expense of 6.4 M or Selling And Marketing Expenses of 6.5 M, as well as many indicators such as Price To Sales Ratio of 2.62, Dividend Yield of 0.0 or PTB Ratio of 3.07. Pharming financial statements analysis is a perfect complement when working with Pharming Group Valuation or Volatility modules.
Pharming | Total Current Liabilities |
Latest Pharming Group's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Pharming Group NV over the last few years. Total Current Liabilities is an item on Pharming Group balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Pharming Group NV are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Pharming Group's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pharming Group's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Pharming Total Current Liabilities Regression Statistics
| Arithmetic Mean | 48,035,471 | |
| Geometric Mean | 34,711,498 | |
| Coefficient Of Variation | 70.95 | |
| Mean Deviation | 28,166,995 | |
| Median | 46,721,088 | |
| Standard Deviation | 34,082,443 | |
| Sample Variance | 1161.6T | |
| Range | 107.4M | |
| R-Value | 0.68 | |
| Mean Square Error | 670.8T | |
| R-Squared | 0.46 | |
| Significance | 0.01 | |
| Slope | 5,189,857 | |
| Total Sum of Squares | 16262.6T |
Pharming Total Current Liabilities History
About Pharming Group Financial Statements
Pharming Group shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Pharming Group investors may analyze each financial statement separately, they are all interrelated. The changes in Pharming Group's assets and liabilities, for example, are also reflected in the revenues and expenses on on Pharming Group's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 78 M | 46.5 M |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.